Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
IOS 9 Exam 3
Insulin Treatment
| Question | Answer |
|---|---|
| Type 1 Insulin dosing TDD | Inital starting 0.5-0.8 Honeymoon phase 0.2-0.5, Ketosis, illiness, adolescent growth 1-1.5 |
| Type 2 dosing for insulin resistance | 0.7-2.5 |
| Basal Insulin-Glargine dosing | Clear, do not mix, QHS (type 2 10Units to start) if with BID NPH decrease 20% |
| NPH vs Insulin Glargine | same efficacy but NPH greater hypoglycemia |
| Type 2 basal titration | 10Units to start then increase of decrease by - >180- up 8, >160-up 6 >140-up 4 and >120 up 2 |
| Rapid acting without insulin resistance | 1Unit will effect 50mg/dL glucose |
| Insulin adjustment of Type 1 & 2 | Basal insulin adjust weekly if needed sooner if AM hypoglycemia |
| Insulin administration techniques | Wash hands, re-suspend, clean bottle, push air in, pull insulin in, remove bubbles, clean skin, pich fold and inject, remove needle,dispose properly, rotate site, draw up fast acting |
| Rapid acting analogues are | Clear and designed to mimic post-prandial insulin secretion |
| Short acting insulin analogues are | clear and contain neutral pH buffer and zince |
| Intermediate acting insulin analogues are | cloudy, conatin zince,protamine and phosphate buffer |
| Long acting insulins are | clear and Glargine is at pH of 4 and causes depot effect slow release, Detemir has FA which binds albumin and slowly releases into liquid depot |
Created by:
liza001
Popular Pharmacology sets